KURA ONCOLOGY, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
KURA ONCOLOGY, INC. (KURA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $10.12 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $10.12M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.07M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.95M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.60M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $10.12M 10-K · filed 2026-03-05 |
| 2024-12-31 | $9.07M 10-K · filed 2026-03-05 |
| 2023-12-31 | $8.95M 10-K · filed 2025-02-28 |
| 2022-12-31 | $6.60M 10-K · filed 2024-02-27 |
| 2021-12-31 | $4.84M 10-K · filed 2023-02-23 |
| 2020-12-31 | $2.64M 10-K · filed 2022-02-24 |
| 2019-12-31 | $2.13M 10-K · filed 2021-02-24 |
| 2018-12-31 | $1.43M 10-K · filed 2020-02-25 |
| 2017-12-31 | $601.00K 10-K · filed 2019-03-05 |
| 2016-12-31 | $267.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |